I refer the hon. Member to replies given on 3 May 2006, Official Report, columns 1701-02W.
Recent assessments by the Medicines and Healthcare products Regulatory Agency (MHRA), in consultation with independent experts, have concluded that the balance of risks and benefits of mifepristone (Mifegyne, RU-486) remains positive, for use in its licensed indications in medical abortion, and that no changes to prescribing advice are needed. The MHRA is aware of deaths that have been reported in association with the use of mifepristone both in the United States (US) and in the United Kingdom. However, as there is no clear evidence that mifepristone has caused these deaths there is no basis for regulatory action or further discussions with the US authorities.